The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under ...
This milestone marks a breakthrough after unsuccessful attempts to develop painkillers without the addictive potential of ...
The FDA has approved Journavx 50 mg oral tablets for the treatment of moderate to severe acute pain in adults, according to a ...
A new class of non-opioid drugs treats pain by blocking signals before they reach the brain, reducing the risk of addiction.
The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) oral tablets on Thursday as a first-in-class ...
The Food and Drug Administration has approved a first-of-its-kind non-opioid pain medication, providing a new option for ...
The drug, shown to be almost as effective as opioids for short-term pain, is the first fundamentally new kind of painkiller ...
Approval of Journavx for acute pain marks the first new class of acute pain medication approved by the FDA in over 20 years.
( The Hill) – The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) oral tablets on Thursday as a first ...
Vertex has gained the FDA's approval for its non-addictive pain med Journavx, which becomes the first significant innovation ...
The FDA has approved Journavx, a new non-opioid pain medication designed to reduce addiction and overdose risks.
Today, the U.S. Food and Drug Administration approved Journavx (suzetrigine) 50 milligram oral tablets, a first-in-class ...